New 52 Week Low Today

Galapagos NV GLPG:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/24/24 EDT
27.27UNCH (UNCH)
Volume
886
Close
27.27quote price arrow down-0.38 (-1.37%)
Volume
90,633
52 week range
27.21 - 44.85
Loading...
  • Open27.43
  • Day High27.46
  • Day Low27.21
  • Prev Close27.65
  • 52 Week High44.85
  • 52 Week High Date05/24/23
  • 52 Week Low27.21
  • 52 Week Low Date05/24/24

Key Stats

  • Market Cap1.797B
  • Shares Out65.90M
  • 10 Day Average Volume0.10M
  • Dividend-
  • Dividend Yield-
  • Beta0.28
  • YTD % Change-32.92

KEY STATS

  • Open27.43
  • Day High27.46
  • Day Low27.21
  • Prev Close27.65
  • 52 Week High44.85
  • 52 Week High Date05/24/23
  • 52 Week Low27.21
  • 52 Week Low Date05/24/24
  • Market Cap1.797B
  • Shares Out65.90M
  • 10 Day Average Volume0.10M
  • Dividend-
  • Dividend Yield-
  • Beta0.28
  • YTD % Change-32.92

RATIOS/PROFITABILITY

  • EPS (TTM)0.50
  • P/E (TTM)54.21
  • Fwd P/E (NTM)-35.58
  • EBITDA (TTM)-91.798M
  • ROE (TTM)1.12%
  • Revenue (TTM)317.258M
  • Gross Margin (TTM)123.06%
  • Net Margin (TTM)10.47%
  • Debt To Equity (MRQ)0.28%

EVENTS

  • Earnings Date08/01/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Galapagos NV

 

Profile

MORE
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. It...
Paulus Stoffels
Chairman of the Board, Chief Executive Officer
Thad Huston
Chief Financial Officer, Chief Operating Officer, Executive Vice President, Member of the Management Board
Valeria Cnossen
Executive Vice President, General Counsel, Member of the Management Board
Address
Generaal De Wittelaan L11 A3
Malines (mechelen)
2800
Belgium

Top Peers

SYMBOLLASTCHG%CHG
MYGN
Myriad Genetics Inc
23.16-0.11-0.47%
NVCR
Novocure Ltd
23.15+0.84+3.77%
ACAD
ACADIA Pharmaceuticals Inc
15.20-0.34-2.19%
TXG
10X Genomics Inc
22.59-0.36-1.57%
CPRX
Catalyst Pharmaceuticals Inc
15.87-0.05-0.31%